Commercial license will allow clinical and commercial production.

Selexis signed a commercial license agreement with Ganymed Pharmaceuticals for use of Selexis’ technology for large-scale production of Ganymed’s lead antibodies.

The deal allows Ganymed to use a high performance cell line, developed by Ganymed scientists using the Selexis SURE cell line development platform, for the clinical and commercial production of a number of products.

Previous articleNanogen Gains Access to Schizophrenia Markers
Next articleSigma-Aldrich and Sangamo Ink Deal to Develop Zinc Finger-Based Lab Research Reagents